How to source pharmaceutical intermediates from China

China remains one of the world’s most important manufacturing bases for pharmaceutical intermediates, fine chemicals, and custom building blocks. The opportunity is real: buyers can reach mature production clusters, specialized reaction capabilities, flexible batch sizes, and alternative routes that may not be available in their home market. The risk is equally real. A supplier that can quote a CAS number is not automatically able to reproduce a process at scale, control route-related impurities, issue reliable documents, or ship the material compliantly.

A sound sourcing decision therefore depends on an evidence chain rather than a persuasive quotation. The buyer must define what the downstream process actually needs, verify who will manufacture the material, test whether the sample represents commercial production, align quality and regulatory responsibilities, and convert all of that into contract and release controls. This guide presents that process as a connected procurement workflow instead of a collection of isolated checks.

Updated September 2026. Use the RFQ example in section 1 to prepare an inquiry, the receiving decisions in section 3 to plan acceptance, and the 100 kg comparison in section 4 to evaluate offers. Section 7 connects the steps into an illustrative 90-day project plan.

Explore Hongkun’s pharmaceutical intermediates catalogue, review the sourcing workflow and ChemsFlow, or begin with a structured RFQ.

1. Define the buying requirement before contacting suppliers

The quality of a sourcing project is usually determined before the first quotation arrives. An RFQ that contains only a product name, CAS number, quantity, and target price leaves every supplier free to make different assumptions. One may quote material at 98% by GC, another at 99% by HPLC area normalization, and a third may include a dry-basis assay while excluding water and residual solvents. The quotations look comparable, but they describe different products.

Start by defining identity, quality, use context, and delivery as one requirement. Identity should include the chemical name, CAS number, molecular structure when synonyms are ambiguous, and an internal material code if the project is confidential. Quality should identify the analytical basis, target assay or purity, named and unspecified impurities, residual solvents, water, metals, stereochemical requirements, appearance, particle characteristics, and any route-related impurity known to affect the next reaction. Use context matters because an early-stage building block for process research does not carry the same controls as a late-stage intermediate supporting a regulated commercial product.

The specification should be connected to downstream performance. A nominal 99% result can hide an isomer that co-elutes under a supplier’s method, a catalyst residue that poisons the next step, a salt form that changes solubility, or water that reduces yield. Share the critical quality attributes that influence reaction conversion, work-up, filtration, color, stability, or final API impurity clearance. Suppliers do not always need the customer’s complete process, but they need enough technical context to understand what failure looks like.

Commercial requirements belong in the same document. State the sample quantity, trial quantity, annual forecast, expected order pattern, target delivery date, destination, preferred Incoterm, packaging, labeling, shelf-life or retest expectations, and the documents required for evaluation and customs clearance. Separate the desired production lead time from qualification, testing, export preparation, booking, transit, and import clearance. This prevents a four-week manufacturing promise from being mistaken for a four-week delivered schedule.

Treat the RFQ as a controlled baseline. When a supplier proposes a different grade, method, package, route, or lead-time assumption, record the deviation rather than allowing it to disappear inside an email thread. This single discipline makes later quotation comparison, sample approval, purchase-order drafting, and complaint handling far more reliable.

A worked RFQ you can adapt

The following is a fictional procurement brief for an unnamed intermediate, not a product specification or a Hongkun customer case. Every numerical limit is illustrative and must be replaced by the buyer's approved, substance-specific requirement.

The useful output is a deviation register, not just a price. If a supplier can meet the HPLC limit but has not tested Imp-A, record that as an unresolved technical gap. Do not silently replace the named-impurity requirement with total purity. Keep the final accepted RFQ revision with the quotation, approved sample and purchase order so that everyone works from the same specification.

2. Build a verifiable supplier evidence chain

China’s chemical supply network includes direct manufacturers, group sales companies, export traders, distributors, laboratories, and integrated sourcing partners. None of those labels proves capability or disqualifies a supplier. The practical question is who controls manufacturing, quality, documentation, payment, export, and corrective action. A buyer should be able to trace each of those responsibilities to a legal entity and an operating site.

Build the initial longlist from several evidence sources: industry databases, patents and technical literature, trade-show records, lawful shipment information, regulatory or certification databases, known manufacturing clusters, existing supplier networks, and direct factory outreach. Search by CAS number, systematic name, synonyms, structure, and likely precursor families. Product-listing websites are useful discovery tools, but a listing is not evidence that the company has made the material recently or at the requested scale.

During first screening, request the legal company name, unified business identifier where applicable, registered address, manufacturing address, contracting and invoicing entity, export entity, main product families, relevant equipment, normal batch range, recent production status, and export experience. Confirm whether the quoted site owns the process or subcontracts a critical step. If a trader is involved, require transparency about the approved manufacturing site and how technical questions, deviations, and complaints reach that site.

Supplier qualification should be proportional to material risk. A standard early-stage intermediate may justify document review, reference checks, and independent sample testing. A route-sensitive late-stage intermediate may require a detailed questionnaire, live video review, onsite audit, quality agreement, data-integrity review, change-notification commitments, and management approval. The audit should focus on the proposed process: reactor material and volume, temperature and pressure range, inerting, distillation, filtration, drying, milling, containment, cleaning, waste treatment, analytical support, critical raw-material controls, and scale-up history. A tour of unrelated equipment adds little value.

Quality-system evidence should show how work is controlled, not merely which certificates are framed on the wall. Review batch records, document control, deviations, out-of-specification investigations, change control, training, calibration, maintenance, data integrity, sample retention, complaints, and traceability. Ask for anonymized examples when appropriate. A credible supplier can explain how an unexpected result moves from laboratory observation to investigation, impact assessment, disposition, and corrective action.

Use a weighted scorecard to keep the decision honest. Technical fit and quality maturity should normally outweigh presentation quality or a small price difference. A practical model might allocate 30% to technical and process fit, 25% to quality and documentation, 15% to sample performance, 15% to commercial terms, 10% to delivery and capacity, and 5% to communication. Adjust those weights to the material’s risk, but agree them before ranking quotations.

Red flags deserve explicit escalation: reluctance to identify the manufacturing site, documents carrying a different company or address, identical analytical results across multiple batches, inconsistent process descriptions, a commercial sample that cannot be linked to the proposed production route, pressure for payment before basic evidence is supplied, or a price that is inexplicably below the normalized market range. One red flag may have an innocent explanation; several unclosed red flags indicate that the evidence chain is not strong enough for approval.

3. Prove material quality before committing to scale

Quality review begins with the agreed specification, not the supplier’s standard COA. A useful COA identifies the product and batch, specification version, test method or method reference, numerical results where possible, manufacturing or retest information, and authorized release. Check whether purity means HPLC area percentage, GC area percentage, assay on an as-is or dried basis, titration, or another calculation. Confirm that units and limits are consistent and that the method can separate the impurities relevant to the buyer’s route.

The SDS answers a different question. It communicates substance identity, hazards, handling, storage, exposure control, emergency response, and transport information. It does not demonstrate batch quality. Review it for the correct substance, composition, classification, transport section, issuing entity, revision date, and destination-language needs. Depending on the project, supporting evidence may also include a product specification, analytical method, chromatograms, residual-solvent statement, elemental-impurity statement, stability information, process-flow summary, origin declaration, animal-origin statement, or regulatory support package. Each document must correspond to the proposed grade and manufacturing site.

A sample is a technical experiment, not a sales souvenir. Define the source batch, manufacturing scale, route, package, shipping condition, and relationship to future commercial supply. If the sample comes from a laboratory route while the order will use a different raw material, catalyst, isolation, or drying step, passing the sample does not qualify the commercial process. For sensitive materials, require a pilot or commercial-equipment sample before full approval.

The test plan should combine identity, specification testing, and downstream-use evaluation. Depending on the molecule, this may include HPLC or GC, quantitative assay, NMR, LC-MS or GC-MS, infrared, water, residual solvents, elemental impurities, inorganic residue, optical rotation or chiral purity, melting range, appearance, and stability. Compare supplier and buyer chromatograms rather than only comparing the final purity number. Unknown peaks, integration settings, reference-standard potency, sample preparation, and calculation basis often explain apparently conflicting results.

Downstream process performance is frequently the decisive test. Record reaction conversion, impurity formation, work-up behavior, phase separation, filtration time, color, drying, yield, and carryover into the next stage. A material can pass a generic sales specification and still be commercially unsuitable. When this occurs, translate the observed process failure into a measurable incoming-material control wherever scientifically justified.

Before shipment, define the release sequence. State who samples the batch, which laboratory tests it, whether a pre-shipment sample is required, what documents must be approved, how long the buyer has to respond, and what happens if results differ. Retained samples and an agreed independent laboratory provide a practical route for disputes. The purchase contract should also state whether shipment before buyer approval is prohibited and who bears storage or rework cost when the batch fails.

Receiving is not the same as release for use

Keep three decisions distinct: permission to dispatch, physical receipt at the warehouse, and quality release for the intended use. A signed delivery receipt records arrival; it does not by itself close a quality investigation or authorize production use.

The fictional examples below use the illustrative RFQ limits above. They show a decision process, not universal acceptance criteria.

Assign the decision to the authorized quality function and document any escalation. Do not average a failing result with a passing result to manufacture compliance, or order repeated tests merely to obtain a pass. Retesting must follow a scientifically justified investigation and the applicable quality procedure. Record the batch number, specification version, reason for hold, owner, next action and disposition date so that purchasing and the warehouse can act on the same status.

4. Compare real economics and negotiate usable contracts

Normalize every quotation before ranking it. The same table should show grade, specification, test scope, manufacturing site, quantity basis, MOQ, package, Incoterm, production lead-time definition, quotation validity, payment terms, sample policy, documentation, and exclusions. If a supplier cannot answer one of those fields, mark it as missing rather than assuming a favorable answer. A low ex-works price may become the most expensive option after inland dangerous-goods transport, export charges, upgraded packaging, testing, bank fees, freight, import handling, and inventory delay.

Total landed cost includes product value, domestic transport, export handling, freight, insurance, duties and taxes, customs brokerage, import testing, storage, and financing. Risk-adjusted cost goes further by estimating the impact of batch rejection, late delivery, requalification, yield loss, deviation investigation, emergency freight, and production interruption. The purpose is not to invent a precise monetary value for every risk; it is to prevent a small visible price advantage from hiding a much larger operational exposure.

Payment terms should reflect evidence and project maturity. New suppliers may ask for deposits because they must purchase dedicated raw materials, but the buyer can link later payments to defined milestones such as raw-material readiness, batch completion, document review, or pre-shipment approval. Confirm the payee against the contracting entity and investigate unexplained requests to pay personal or unrelated accounts. For high-value custom work, define ownership of dedicated raw materials, failed batches, intermediates, tooling, analytical development, and project intellectual property.

The purchase order and quality agreement must translate the sourcing decision into enforceable controls. Identify the approved legal entity and manufacturing site, material and specification version, methods, package, labels, quantity tolerance, release documents, Incoterm, delivery window, change-notification period, deviation and complaint process, audit rights, confidentiality, record retention, and remedies for nonconforming or delayed supply. State which changes require prior approval: route, critical raw material, production site, key equipment, subcontractor, analytical method, specification, packaging, or storage condition.

Do not leave laboratory disagreement to improvisation. The contract should define sampling, retesting, use of retained samples, the independent laboratory, allocation of test cost, and final disposition. Likewise, define what constitutes an excusable delay and when the supplier must provide an updated recovery plan. Incoterms allocate important transport responsibilities, but they do not replace these quality and operational clauses.

A balanced award decision can split volume between a primary and secondary source when the business case supports it. The second source may appear more expensive in routine conditions but can preserve continuity during capacity shortages, regulatory disruptions, raw-material failures, or route-specific quality problems. Continuity has a cost; so does discovering during a crisis that no alternative has been sampled or qualified.

Worked example: compare the same 100 kg order

This fictional USD comparison assumes that both suppliers have already met the same specification and sample requirements. The amounts are invented to demonstrate the calculation; they are not market quotations, freight estimates or Hongkun transaction data. Compare the same quantity, destination terminal, currency and quotation date.

A appears USD 600 cheaper on product value; B is USD 300 cheaper across the cost scope shown. This subtotal excludes duties, import taxes, brokerage, destination handling, final delivery, storage and financing. Add those separately before calling the result total landed cost, and avoid adding a charge twice when it is already included. Mark unknown amounts as pending instead of zero. If either offer has an unresolved quality gap, pause its commercial ranking until technical comparability is established.

In the real contract, specify the exact named place and Incoterms version; the abbreviated site descriptions above are only for the calculation. Incoterms allocate delivery obligations, costs and risk, but do not determine ownership transfer, payment terms or product specifications. Those provisions belong in the contract. ICC's explanation of Incoterms and commercial contracts.

5. Align compliance, packaging, and logistics as one workstream

Regulatory and transport questions should begin during supplier screening, not after the batch is ready. Requirements depend on substance, quantity, intended use, destination, and the legal role of each party. For pharmaceutical use, clarify whether the material is treated as a starting material, intermediate, API starting material, or API within the buyer’s control strategy. The label used in a quotation does not decide its regulatory role. Quality and regulatory teams should define the evidence, audit access, change control, and filing support needed for the intended market.

For the European Economic Area, REACH responsibilities may fall on the importer unless relevant coverage exists through an only representative or another valid arrangement. Registration status, tonnage, use, restrictions, authorization, classification, labeling, and supply-chain communication need substance-specific review. Other destinations may apply chemical inventories, controlled-substance or precursor rules, sanctions, export controls, and local notification requirements. Confirm the customs code and origin evidence, but do not assume that a previous shipment to the same country proves compliance for a new buyer and use.

Packaging is part of product quality. Select the primary and secondary package based on sensitivity to moisture, oxygen, light, temperature, contamination, and physical damage. Specify liner material, closure, tamper evidence, desiccant, nitrogen protection, net weight, label content, palletization, and temperature monitoring where relevant. Confirm whether the supplier has used that package at the quoted scale and whether it is compatible with dangerous-goods and carrier requirements. Photographs of the final packed batch can prevent simple but costly errors.

Dangerous-goods classification must rely on defensible data for the transport mode. Air, sea, road, rail, courier, and postal channels do not apply identical operational rules. Review the SDS transport section, but obtain additional classification evidence when carriers or regulations require it. Booking material as non-dangerous merely because a supplier used that description can lead to rejection, delay, penalties, repacking, or safety risk.

Build the delivery schedule from its components: critical raw-material procurement, production queue, manufacturing, testing and release, buyer document review, packaging, export preparation, carrier booking, transit, customs clearance, and final delivery. Add decision dates and owners. This schedule shows where expediting can help and where it cannot. It also supports rational safety stock and avoids treating every delay as a factory production problem.

Before dispatch, run a document-and-package check covering invoice, packing list, COA, SDS, origin and transport documents, consignee details, marks, net and gross weights, package count, batch numbers, seal condition, and booking information. A ten-minute cross-check between commercial, quality, and logistics teams can prevent days of customs or warehouse delay.

Clarify the applicable quality and registration scope

A pharmaceutical use does not, by itself, make every upstream chemical an ICH Q7 material. Q7 links its GMP scope to the documented point at which the API starting material enters the process. Define that point and the purchased material's role with the buyer's quality and regulatory teams before requesting specific GMP evidence. FDA Q7 guidance.

Under REACH, calling a substance an intermediate does not automatically remove registration obligations. Reduced information requirements for qualifying isolated intermediates depend on the applicable conditions, including strictly controlled conditions. An only representative's coverage must also match the relevant substance, supplier and import chain; it does not follow from a generic supplier statement. ECHA guidance on intermediates and only representatives.

The GHS is a hazard-classification and communication framework. Its latest UN revision does not automatically become the legally applicable edition in every destination; verify local implementation when checking an SDS or label. UNECE GHS Revision 11 (2025).

6. Move from sample success to dependable commercial supply

Scale-up changes the physical environment of a process. Heat transfer, mixing, addition time, mass transfer, crystallization, filtration, washing, and drying may behave differently at commercial volume. Confirm whether the approved sample came from laboratory, pilot, or commercial equipment and identify the steps most likely to change the impurity profile or physical form. For custom synthesis, use staged gates—route review, laboratory demonstration, pilot batch, engineering or validation batch where appropriate, then routine production—rather than jumping directly from milligrams to tonnes.

The first commercial order should be treated as a qualification batch. Apply enhanced review to raw materials, in-process controls, yield, deviations, chromatograms, package, and transport. Compare commercial results with the approved sample and document any new peaks or process differences. If the material passes only after an unplanned rework, determine whether the rework is scientifically understood and permitted before accepting it as the future standard process.

After approval, manage the supplier with trend data. Useful measures include on-time-in-full delivery, right-first-time quality, deviation and complaint frequency, document accuracy, response time, change-notification performance, price stability, and corrective-action closure. Review trends across batches rather than judging each COA in isolation. Gradual movement in water, a known impurity, color, or yield can signal raw-material or process drift before a formal specification failure occurs.

Change control protects the evidence chain built during qualification. Require written notice for changes to the site, route, critical raw-material source, equipment train, subcontractor, batch scale, analytical method, specification, package, or storage. The buyer should assess whether the change requires documents, comparative testing, a new sample, stability work, regulatory review, or requalification. A COA that still passes does not automatically show that a change is harmless to downstream performance.

Continuity planning should identify single points of failure: a unique precursor, one reactor line, seasonal campaign, sole analytical standard, restricted logistics route, or financially fragile subcontractor. Decide whether to qualify a second source, reserve capacity, hold safety stock, secure critical raw materials, or maintain an emergency communication and allocation plan. Forecast sharing can improve supplier planning, but forecasts should be realistic and linked to clear order commitments.

The best long-term supplier relationships combine accountability with joint problem solving. Buyers should provide timely, technically useful feedback rather than vague rejection notices. Suppliers should disclose problems early, protect traceability, and propose evidence-based corrective actions. Over time, this approach produces more value than repeatedly moving volume to the lowest spot quotation.

7. A practical 90-day sourcing playbook

A disciplined project can move quickly without skipping controls. During days 1–10, finalize the requirement, risk classification, confidentiality approach, target market, budget, and decision criteria. Build the longlist and issue one controlled RFQ package. During days 11–25, verify identities and sites, collect documents, normalize quotations, close major information gaps, and select candidates for sampling. Avoid carrying weak suppliers forward merely to preserve a large candidate count.

During days 26–50, receive and test samples, compare analytical data, run the downstream-use study, and complete risk-based supplier qualification. In parallel, confirm regulatory responsibilities, dangerous-goods assumptions, packaging, and delivered-cost scenarios. The technical and commercial teams should review the same evidence set; otherwise one group may approve a product that the other group has priced or scoped differently.

During days 51–70, select the preferred source, negotiate the purchase order and quality agreement, define the release plan, and close audit actions. If a secondary source is justified, keep it active through sampling rather than leaving it as an unverified name on a spreadsheet. During days 71–90, place and monitor the trial or first commercial order, review production and pre-shipment evidence, authorize dispatch, and capture lessons after receipt. The exact timeline will vary, but explicit gates prevent commercial urgency from silently deleting technical controls.

Use the following final approval questions:

• Do we know the legal seller, manufacturer, production site, export party, and quality owner?
• Are the specification and methods connected to downstream process needs?
• Does the approved sample represent the intended commercial route and scale?
• Have supplier and buyer results been reconciled, including unknown impurities?
• Are regulatory, customs, dangerous-goods, packaging, and destination requirements assigned to named owners?
• Does the contract control site, route, raw materials, release, change notification, claims, and laboratory disputes?
• Is the delivered schedule built from real production, review, booking, and transit steps?
• Is there a proportionate continuity plan for a critical material?

Hongkun Chemicals supports overseas buyers across this workflow: clarifying requirements, identifying Chinese manufacturing options, checking supplier and site evidence, normalizing quotations, collecting and reviewing COA and SDS packages, coordinating samples, aligning technical questions, and following packaging and logistics through delivery. ChemsFlow organizes supplier evidence and comparisons so that a recommendation can be traced back to the underlying technical, quality, commercial, and delivery facts. Human review remains central because chemical sourcing decisions depend on context and judgment.

Need a qualified source for a pharmaceutical intermediate?
Send the CAS number, specification, quantity, destination, target schedule, and required documents through our Request a Quote workspace. We will structure the requirement and coordinate a sourcing response based on technical fit, supplier evidence, commercial terms, and delivery feasibility.

Authoritative references

• FDA: Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients
• UNECE: Globally Harmonized System of Classification and Labelling of Chemicals, Revision 11 (2025)
• European Commission: REACH Regulation
• ECHA: Guidance on intermediates
• ECHA: Only representative
• ICC: Incoterms and commercial contracts

Editorial and regulatory disclaimer: This guide provides general procurement information and is not legal, regulatory, quality, safety, or transportation advice. Requirements vary by substance, process stage, quantity, destination, intended use, and the legal role of each party. Obtain appropriate professional review before purchasing or importing chemicals.